相关ETF ● 估值分位: 55.62% 科创100ETF华夏 基金有风险,投资需谨慎. 近五日涨跌：5.37% 市盈率：227.43倍 资金流向：最新份额为27.0亿份，减少了5000.0万份，主力资金 净流入385.2万元。 (产品代码: 588800) ★ 跟踪：上证科创板100指数 ...

相关ETF ● 科创100ETF华夏 (产品代码: 588800) ★ 跟踪：上证科创板100指数 近五日涨跌：5.37% 市盈率：227.43倍 资金流向：最新份额为27.0亿份，减少了5000.0万份，主力资金 净流入385.2万元。 估值分位: 55.62% 基金有风险,投资需谨慎. ...

证券代码：688516 证券简称：奥特维 公告编号：2025-086 转债代码：118042 转债简称：奥维转债 无锡奥特维科技股份有限公司 向特定对象发行 A 股股票之限售股解禁上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 重要内容提示： ? 本次股票上市类型为向特定对象发行股份；股票认购方式为网 下，上市股数为22,678,515股 。 ? 本次上市流通的限售股股份数量及股份占比以公司最新的股本 总数 315,196,071 股计算。 本次股票上市流通总数为22,678,515股。 ? 本次股票上市流通日期为2025 年 9 月 1 日。 一、本次上市流通的限售股类型 监会" ）出具《关于同意无锡奥特维科技股份有限公司向特定对象发行 股票注册的批复》（证监许可[2022]1250 号），同意无锡奥特维科技股 份有限公司（以下简称"公司"或"奥特维"）向特定对象发行股票的 注册申请。此次公司向葛志勇先生发行新增股份 7,704,608 股，本次 发行新增股份的登记托管手续已于 2022 年 9 月 1 ...

深圳惠泰医疗器械股份有限公司2025 年半年度报告摘要 公司代码：688617 公司简称：惠泰医疗 深圳惠泰医疗器械股份有限公司 深圳惠泰医疗器械股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第三节"管理层讨论与分析"中"四、风险因素"相关内容。 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 否 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 A股 上海证券交易所科创板 惠泰医疗 688617 不适用 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书（信息披露境内代表） 证券事务代表 姓名 戴振华 陈然然 电话 0755-86951506 0755-86951506 深圳市南山区西丽街道松坪山社区松 深圳市南山区西丽街道松坪山社区松 办公地址 坪山朗山路11号同方信息港B栋601 坪山朗山路11号同方 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index increased by 0.71%, with notable stock performances including Zhuhai Guanyu up 6.42% and BZJ Engineering up 5.88% [1] - The Huaxia Sci-Tech 100 ETF (588800) rose by 0.62%, with a recent price of 1.13 yuan, and has seen a cumulative increase of 2.55% over the past week [1] - The Huaxia Sci-Tech 100 ETF's trading volume reached 50.33 million yuan, with an average daily trading volume of 265 million yuan over the past year [1] Group 2 - The National Healthcare Security Administration announced the latest progress in the adjustment of the 2025 National Basic Medical Insurance Directory, with 534 drug names passing the preliminary review, a significant increase from 249 in 2024 [2] - The CXO industry in China is experiencing an adjustment phase due to a cooling in pharmaceutical market investments and high base effects from COVID-19 orders, with a recovery in overseas market demand expected by the end of 2023 [2] - The active Hong Kong stock market and the reopening of listing channels for unprofitable companies on the Sci-Tech Innovation Board are anticipated to further stimulate domestic demand, leading to a new development phase for the CXO industry chain [2]

Group 1 - The core viewpoint of the article highlights the performance and characteristics of the Huaxia STAR 100 ETF, which tracks the Shanghai Stock Exchange STAR 100 Index [2] - The ETF has experienced a recent five-day increase of 1.78% [2] - The current price-to-earnings ratio of the ETF stands at 212.99 times [2] - The latest share volume of the ETF is 2.7 billion shares, reflecting a decrease of 17.5 million shares [2] - There has been a net outflow of 9.97 million yuan in principal funds [2] Group 2 - The valuation percentile of the ETF is reported at 42.50% [3]

珠海冠宇电池股份有限公司监事会/董事会薪酬与考核委员会 关于公司 2025 年股票期权与限制性股票激励计划（草案）的核 查意见 珠海冠宇电池股份有限公司（以下简称"公司"）监事会/董事会薪酬与考核 委员会依据《中华人民共和国公司法》 （以下简称" 《公司法》"）、 《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法 则》"）、 律、法规、规章及规范性文件和《珠海冠宇电池股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，对公司《2025 年股票期权与限制性股票激励计划 （草案）》（以下简称"《激励计划（草案）》"）进行了核查，发表核查意见如下： 实施股权激励计划的情形，包括： （1）最近一个会计年度财务会计报告被注册会 计师出具否定意见或者无法表示意见的审计报告； （2）最近一个会计年度财务报 告内部控制被注册会计师出具否定意见或无法表示意见的审计报告； （3）上市后 最近 36 个月内出现过未按法律法规、公司章程 ...

Group 1 - The company held its 31st meeting of the second board on August 8, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2] - The board approved the draft of the 2025 Stock Option and Restricted Stock Incentive Plan to enhance long-term incentive mechanisms and attract talent, with a voting result of 5 in favor, 0 against, and 4 abstentions [1][2] - The board also approved the implementation assessment management measures for the 2025 incentive plan, with the same voting results as above [1][2] Group 2 - The board proposed to authorize the board to handle matters related to the 2025 Stock Option and Restricted Stock Incentive Plan, including determining eligibility and conditions for participants, with a voting result of 5 in favor, 0 against, and 4 abstentions [2][3] - The company plans to hold its first extraordinary general meeting of 2025 on August 25, 2025, to review related proposals, with unanimous support from all directors [3]

Core Viewpoint - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index experienced a decline of 0.41% as of August 7, 2025, with mixed performance among constituent stocks, indicating a volatile market environment [1] Group 1: Market Performance - Dongxin Co., Ltd. reached the daily limit increase, while Nanchip Technology and Funeng Technology rose by 8.91% and 6.96%, respectively [1] - On the downside, Borui Pharmaceutical led the decline with a drop of 7.38%, followed by Xiamen Tungsten and Shenzhou Cell, which fell by 4.77% and 4.57% [1] - The Huaxia Sci-Tech 100 ETF (588800) decreased by 0.36%, with a latest price of 1.1 yuan, but saw a weekly increase of 3.28% as of August 6, 2025 [1] Group 2: Liquidity and Scale - The Huaxia Sci-Tech 100 ETF (588800) had a turnover rate of 6.8% during the trading session, with a transaction volume of 202 million yuan [1] - The average daily transaction volume for the ETF over the past month was 171 million yuan [1] - The ETF's scale increased by 12 million yuan over the past two weeks, indicating significant growth [1] Group 3: Industry Insights - The Shanghai Municipal Government released the "Implementation Plan for the Development of Embodied Intelligence Industry," aiming to accelerate the development of core components and intelligent terminal products [1] - According to Dongfang Securities, the rise of generative AI is driving explosive demand for computing infrastructure, benefiting sectors such as servers, PCBs, and storage [1] - The industry is witnessing a recovery in terminal shipment volumes for PCs and smartphones due to inventory depletion and replenishment demand, alongside a rebound in storage prices [1] - There is a focus on three key areas: AI innovation chain, domestic substitution, and cyclical recovery, with optimism regarding the replacement cycle in traditional consumer electronics driven by AI applications [1]

Group 1 - The company held meetings on July 11, 2025, to approve the stock incentive plan and related proposals [1] - The company publicly disclosed the draft of the 2025 stock incentive plan and the list of proposed incentive recipients on July 12, 2025 [1][2] - The public notice period for the proposed incentive recipients lasted from July 12 to July 21, 2025, during which employees could raise objections [1][2] Group 2 - The supervisory board received no objections from employees regarding the proposed incentive recipients by the end of the public notice period [2] - The supervisory board verified the eligibility of the proposed recipients based on their identification documents, employment contracts, and positions held within the company [2][3] - The supervisory board concluded that all proposed recipients met the conditions set forth in relevant laws and regulations, as well as the company's internal policies [3]